news Potential COVID-19 treatment and vaccine combination shows success in cells 12 August 2020 | By Victoria Rees (Drug Target Review) A possible treatment and vaccine combination for COVID-19 has shown positive results in pre-clinical studies using human cells.
news Apilimod small molecule shows potent inhibition of SARS-CoV-2 in cells 7 August 2020 | By Victoria Rees (Drug Target Review) Researchers have found the small molecules Apilimod and Vacuolin-1 inhibited the PIKfyve kinase in cells, preventing infection from Zaire ebolavirus and SARS-CoV-2.
news Decoy ACE2 receptors show promise as COVID-19 treatment in cell cultures 5 August 2020 | By Victoria Rees (Drug Target Review) A new decoy receptor of ACE2 has been created which binds to and neutralises COVID-19 in live tissue cultures, preventing cells from becoming infected.
news Protease inhibitors with antiviral activity against coronaviruses developed 4 August 2020 | By Victoria Rees (Drug Target Review) Researchers have created compounds called 3C-like protease inhibitors which demonstrated antiviral activity against several coronaviruses in cells, including COVID-19.
news Functioning lung cell assay for modelling COVID-19 infections developed 31 July 2020 | By Victoria Rees (Drug Target Review) A UK company has announced that their lung epithelium model can successfully be used to test potential treatments for COVID-19.
news PLpro inhibitors support immune response to COVID-19 in cell cultures 30 July 2020 | By Victoria Rees (Drug Target Review) Researchers have found that using GRL-0617, an PLpro inhibitor, in cell cultures blocked SARS-CoV-2 production and supported the cell immune response.
news LY6E identified as potential immunoprotein against SARS-CoV-2 29 July 2020 | By Victoria Rees (Drug Target Review) A study has demonstrated that the LY6E protein inhibits SARS-CoV-2 infection in human cell cultures, so a drug mimicking it could be a therapy for COVID-19.
news High-throughput screening reveals 21 drugs with activity against COVID-19 28 July 2020 | By Victoria Rees (Drug Target Review) After screening 12,000 existing drugs, scientists have identified 21 which prevent the replication of SARS-CoV-2 in concentrations safe for patients.
news Seaweed extract outperforms remdesivir as COVID-19 therapy in vitro 27 July 2020 | By Victoria Rees (Drug Target Review) According to new research, sulfated polysaccharides extracted from seaweed were more effective at inhibiting SARS-CoV-2 infection in mammalian cells than remdesivir.
news Chloroquine does not prevent SARS-CoV-2 infection in human lung cells, study finds 23 July 2020 | By Victoria Rees (Drug Target Review) A new study has shown that while chloroquine protects African green monkey kidney cells from SARS-CoV-2 infection, it does not protect human lung cells.
news CBD may combat cytokine storms and respiratory distress caused by COVID-19 17 July 2020 | By Hannah Balfour (Drug Target Review) Scientists found in a murine model of acute respiratory distress syndrome (ARDS) that cannabidiol (CBD) helped the lungs recover from excessive inflammation caused by COVID-19.
news Interferon deficiency and heightened inflammation are hallmarks of severe COVID-19, say researchers 15 July 2020 | By Hannah Balfour (Drug Target Review) The newly identified hallmarks of critical COVID-19 indicate a combination of interferon supplementation and anti-inflammatory therapies could be effective in treating patients with severe COVID-19 symptoms.
news Most antibodies targeting SARS-CoV-2 use specific immunoglobulin subtype 14 July 2020 | By Hannah Balfour (Drug Target Review) Researchers reveal IgHV3-53 is the most common immunoglobulin mutation used to target the receptor binding domain on the SARS-CoV-2 spike protein.
news Pre-clinical study supports remdesivir as COVID-19 treatment 13 July 2020 | By Hannah Balfour (Drug Target Review) Scientists demonstrated that remdesivir can inhibit SARS-CoV-2 replication in human lung cells and improve lung function in mice with COVID-19.
news Study identifies eight novel coronavirus replication terminators 6 July 2020 | By Hannah Balfour (Drug Target Review) Scientists reveal eight new molecules, five of which are already US FDA-approved, that can block the polymerase reaction SARS-CoV-2 uses to replicate its genome.
